Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Bicycle Therapeutics stock
Learn how to easily invest in Bicycle Therapeutics stock.
Bicycle Therapeutics plc is a biotechnology business based in the US. Bicycle Therapeutics shares (BCYC) are listed on the NASDAQ and all prices are listed in US Dollars. Bicycle Therapeutics employs 109 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Bicycle Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BCYC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Bicycle Therapeutics stock price (NASDAQ: BCYC)Use our graph to track the performance of BCYC stocks over time.
Bicycle Therapeutics shares at a glance
|Latest market close||$46.91|
|52-week range||$20.67 - $62.08|
|50-day moving average||$55.64|
|200-day moving average||$40.83|
|Wall St. target price||$73.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.87|
Buy Bicycle Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Bicycle Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bicycle Therapeutics price performance over time
|1 week (2022-01-18)||0.56%|
|1 month (2021-12-23)||-22.17%|
|3 months (2021-10-25)||-12.58%|
|6 months (2021-07-23)||32.85%|
|1 year (2021-01-25)||73.87%|
|2 years (2020-01-24)||336.37%|
|3 years (2019-01-21)||N/A|
|5 years (2017-01-21)||N/A|
Bicycle Therapeutics financials
|Revenue TTM||$11.8 million|
|Gross profit TTM||$-22,759,000|
|Return on assets TTM||-17.9%|
|Return on equity TTM||-47.23%|
|Market capitalisation||$1.4 billion|
TTM: trailing 12 months
Bicycle Therapeutics share dividends
We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.
Bicycle Therapeutics share price volatility
Over the last 12 months, Bicycle Therapeutics's shares have ranged in value from as little as $20.6701 up to $62.075. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bicycle Therapeutics's is -0.2565. This would suggest that Bicycle Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Bicycle Therapeutics has bucked the trend.
Bicycle Therapeutics overview
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics in the news
Earnings playbook: A complete guide to this week's reports, including the first of tech
Markets are expected to remain on edge as the Fed meets in the week ahead
HighMark Wealth Management LLC Buys iShares Russell 2000 ETF, SeaSpine Holdings Corp, Model N ...
Frequently asked questionsWhat percentage of Bicycle Therapeutics is owned by insiders or institutions?
Currently 13.474% of Bicycle Therapeutics shares are held by insiders and 61.175% by institutions. How many people work for Bicycle Therapeutics?
Latest data suggests 109 work at Bicycle Therapeutics. When does the fiscal year end for Bicycle Therapeutics?
Bicycle Therapeutics's fiscal year ends in December. Where is Bicycle Therapeutics based?
Bicycle Therapeutics's address is: Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT What is Bicycle Therapeutics's ISIN number?
Bicycle Therapeutics's international securities identification number is: US0887861088
More guides on Finder
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Ask an Expert